首页 | 本学科首页   官方微博 | 高级检索  
     


Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia
Authors:Ciudad Antonio  San Luis  Bernardo Miguel  Olivares José M  Polavieja Pepa  Valladares Amparo  Gilaberte Inmaculada
Affiliation:Department of Clinical Research and Development, Lilly, S.A. Avenida de la Industria, 30, 28108 Alcobendas, Spain. ciudad_antonio@lilly.com
Abstract:

Objectives

To evaluate the incidence rate of relapse, the clinical profiles, and the therapeutic interventions employed for patients with schizophrenia deemed as likely nonadherers to oral antipsychotic drugs.

Methods

A cohort of 597 outpatients whose therapy was modified because of a psychiatrist-perceived risk of nonadherence was followed for 12 months in an observational study. Baseline correlates of subsequent relapse were analyzed with Cox regression.

Results

At baseline, patients' mean (SD) age and time since diagnosis were 40.1 (11.1) and 15.2 (10.0) years, respectively; 63.7% were males. The Clinical Global Impression scale-Severity (CGI-S) score was ≥ 4 in 87.3% of the patients. Antipsychotic drugs were modified in 506 patients (84.8%); nonpharmacologic therapies were modified in 190 patients (31.8%). In both cases, the primary reason for the modifications was insufficient efficacy of current therapeutic regimen. The proportion of patients in oral antipsychotic monopharmacy decreased from 83.8% to 57.6%; 15.4% started long-acting (depot) formulations. Over the 12-month observation period, 90 patients (15.1%) relapsed. The hazard rate of relapse was higher in patients with substance use disorder or familial psychiatric antecedents and lower in patients who underwent modifications of nonpharmacological therapies or with negative attitude toward antipsychotic medication at baseline.

Conclusions

Effective interventions to prevent relapse in patients with long-standing schizophrenia involving therapeutic challenges related to nonadherence are feasible. Rationale for the baseline correlates, and cues for clinical prevention of relapse in these patients are provided.
Keywords:CATIE, Clinical Antipsychotic Trial of Intervention Effectiveness   CGI-S, Clinical Global Impression scale-Severity   CI, confidence interval   DAI-10, 10-item Drug Attitude Inventory   DSM-IV-TR, Revised text of the fourth edition of the American Psychiatric Association's Diagnostic and Statistical manual for Mental Disorders   EQ-5D, EuroQol-5 Dimensions health-related quality of life instrument   PAS, Premorbid Adjustment Scale   SANS, Scale for the Assessment of Negative Symptoms   SAPS, Scale for the Assessment of Positive Symptoms   SD, Standard Deviation   SOFAS, Social and Occupations Functional Assessment Scale   SUMD, Scale to Assess Unawareness of Illness in Mental Disorders   VAS, Visual Analogue Scale
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号